Laxmi Khanna1*, Chandrashekar Agrawal2, Mandaville Gourie-Devi3 and Ankkita Sharma Bhandari4
1Consultant Neurologist and Neurophysiologist, Department of Neurophysiology, Sir Ganga Ram Hospital, New Delhi, India
2Chairman and Senior Consultant Neurologist, Department of Neurology, Sir Ganga Ram Hospital, New Delhi, India
3Chairperson, Department of Neurophysiology and Retired Consultant Neurologist, Sir Ganga Ram Hospital, New Delhi, India
4Associate Consultant, Department of Neurophysiology, Sir Ganga Ram Hospital, New Delhi, India
*Corresponding Author: Laxmi Khanna, Consultant Neurologist and Neurophysiologist, Department of Neurophysiology, Sir Ganga Ram Hospital, New Delhi, India.
Received: July 07, 2021; Published: July 18, 2021
Citation: Laxmi Khanna., et al. “Seronegative Autoimmune Encephalitis: A Challenge for the Neurologist". Acta Scientific Clinical Case Reports 2.8 (2021): 57-60.
&nbp; Autoimmune neurological disorders are diagnosed by antibody testing in serum and cerebrospinal fluid. However, autoimmune encephalitis and refractory autoimmune epilepsies maybe seronegative in 50% cases despite the use of the currently available serological tests. The Antibody Prevalence in Epilepsy and Encephalopathy Score [APE2] and Response to immunotherapy in epilepsy and encephalopathy scores [RITE2] enhance the value of early case detection and prevent residual neurological damage in patients with recent cognitive decline or refractory epilepsy. We incorporated these scales to improve efficacy in diagnosing autoimmune-mediated neurological diseases in clinical practice. These parameters hasten the diagnosis of autoimmune spectrum of diseases when used on patients attending busy neurology clinics. The scales enable prognostication and assessment of neurological sequel when applied at follow-up. The improvement of symptoms in the autoimmune spectrum of neurological diseases can be attributed to early case detection and institution of appropriate therapy.
Keywords: Seronegative Autoimmune Encephalitis; Progressive Supranuclear Palsy; Anti-IgLON5 Disease
Copyright: © 2021 Laxmi Khanna., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.